The Blood Preparation Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product (Whole Blood, Blood Components, Blood Derivatives), By Antithrombotic and Anticoagulants Type (Platelet Aggregation Inhibitors, Fibrinolytics, Anticoagulants), By Application (Thrombocytosis, Pulmonary Embolism, Renal Impairment, Angina Blood Vessel Complications, Others).
The Blood Preparation market in 2024 serves the demand for blood processing and separation devices used in blood banks, transfusion centers, and clinical laboratories to prepare and fractionate whole blood into various blood components such as packed red blood cells (PRBCs), platelet concentrates, fresh frozen plasma (FFP), and cryoprecipitate for transfusion therapy and therapeutic applications. Blood preparation devices encompass automated blood component separators, centrifuges, leukoreduction filters, and blood storage systems, designed to ensure the safe, efficient, and compliant processing of blood products while maintaining product integrity and quality. Market dynamics are driven by factors such as the increasing demand for blood transfusions and blood products in surgical and medical procedures, advancements in blood processing technology and automation, and regulatory mandates for blood safety and quality control. Collaboration between medical device manufacturers, blood banks, and regulatory agencies drives innovation and market growth in blood preparation, supporting safe and reliable blood supply chains and transfusion medicine practices worldwide.
A prominent trend in the Blood Preparation market is the increasing demand for blood products. Blood and its components are crucial for various medical procedures, including transfusions, surgeries, and treatments for hematological disorders. With advancements in medical technology and an aging population, the demand for blood preparations such as packed red blood cells, platelets, and plasma derivatives is on the rise. This trend is driven by the growing prevalence of chronic diseases, surgical procedures, and trauma cases, necessitating adequate supplies of safe and high-quality blood products to meet patient needs.
A key driver for the Blood Preparation market is the growing awareness and adoption of blood transfusions. Blood transfusions are essential for managing conditions such as anemia, bleeding disorders, and certain cancers, as well as for supporting patients undergoing surgery or experiencing severe trauma. Increasing awareness among healthcare professionals and patients about the benefits of blood transfusions, coupled with advancements in transfusion medicine practices, has led to a higher utilization of blood products in healthcare settings. Additionally, the implementation of stringent regulations and standards for blood collection, processing, and storage has bolstered confidence in the safety and efficacy of blood preparations, further driving market growth.
One potential opportunity in the Blood Preparation market lies in the expansion of the blood donor pool and donation practices. Despite the growing demand for blood products, many regions face challenges related to blood shortages and insufficient donor supplies. To address this issue, there is an opportunity to implement initiatives aimed at recruiting and retaining blood donors, diversifying donor populations, and enhancing donation practices. Strategies such as community outreach programs, mobile blood drives, and the use of digital platforms for donor recruitment and engagement can help increase blood donations and ensure an adequate supply of blood preparations. By tapping into this opportunity, blood centers and healthcare organizations can contribute to improving patient outcomes and reducing the burden of blood product shortages.
By Product
Whole Blood
-Red Cells
-Granulocytes
-Plasma
-Platelets
Blood Components
-Whole Blood Components
-Packed Red Cells
-Leukocyte Reduced Red Blood Cells
-Frozen Plasma
-Platelet Concentrate
-Cryoprecipitate
Blood Derivatives
By Antithrombotic and Anticoagulants Type
Platelet Aggregation Inhibitors
-Glycoprotein Inhibitors
-COX Inhibitors
-ADP Antagonists
-Others
Fibrinolytics
-Tissue Plasminogen Activator (tPA)
-Streptokinase
-Urokinase
Anticoagulants
-Heparins
-Unfractionated Heparin
-Low Molecular Weight Heparin (LMWH)
-Ultra-low Molecular Weight Heparin
-Vitamin K Antagonists
-Direct Thrombin Inhibitors
-Direct Factor Xa Inhibitors
By Application
Thrombocytosis
Pulmonary Embolism
Renal Impairment
Angina Blood Vessel Complications
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
AstraZeneca plc
Baxter International Inc
Bristol-Myers Squibb Company
Celgene Corp
GlaxoSmithKline PLC
Leo Pharma A/S
Pfizer Inc
Portola Pharmaceuticals Inc
Sanofi
Shandong East Chemical Industry Co.
Xiamen Hisunny Chemical Co. Ltd
*- List Not Exhaustive
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Blood Preparation Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Blood Preparation Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Blood Preparation Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Blood Preparation Market Size Outlook, $ Million, 2021 to 2030
3.2 Blood Preparation Market Outlook by Type, $ Million, 2021 to 2030
3.3 Blood Preparation Market Outlook by Product, $ Million, 2021 to 2030
3.4 Blood Preparation Market Outlook by Application, $ Million, 2021 to 2030
3.5 Blood Preparation Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Blood Preparation Market Industry
4.2 Key Market Trends in Blood Preparation Market Industry
4.3 Potential Opportunities in Blood Preparation Market Industry
4.4 Key Challenges in Blood Preparation Market Industry
5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Blood Preparation Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Blood Preparation Market Outlook By Segments
7.1 Blood Preparation Market Outlook by Segments
By Product
Whole Blood
-Red Cells
-Granulocytes
-Plasma
-Platelets
Blood Components
-Whole Blood Components
-Packed Red Cells
-Leukocyte Reduced Red Blood Cells
-Frozen Plasma
-Platelet Concentrate
-Cryoprecipitate
Blood Derivatives
By Antithrombotic and Anticoagulants Type
Platelet Aggregation Inhibitors
-Glycoprotein Inhibitors
-COX Inhibitors
-ADP Antagonists
-Others
Fibrinolytics
-Tissue Plasminogen Activator (tPA)
-Streptokinase
-Urokinase
Anticoagulants
-Heparins
-Unfractionated Heparin
-Low Molecular Weight Heparin (LMWH)
-Ultra-low Molecular Weight Heparin
-Vitamin K Antagonists
-Direct Thrombin Inhibitors
-Direct Factor Xa Inhibitors
By Application
Thrombocytosis
Pulmonary Embolism
Renal Impairment
Angina Blood Vessel Complications
Others
8 North America Blood Preparation Market Analysis And Outlook To 2030
8.1 Introduction to North America Blood Preparation Markets in 2024
8.2 North America Blood Preparation Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Blood Preparation Market size Outlook by Segments, 2021-2030
By Product
Whole Blood
-Red Cells
-Granulocytes
-Plasma
-Platelets
Blood Components
-Whole Blood Components
-Packed Red Cells
-Leukocyte Reduced Red Blood Cells
-Frozen Plasma
-Platelet Concentrate
-Cryoprecipitate
Blood Derivatives
By Antithrombotic and Anticoagulants Type
Platelet Aggregation Inhibitors
-Glycoprotein Inhibitors
-COX Inhibitors
-ADP Antagonists
-Others
Fibrinolytics
-Tissue Plasminogen Activator (tPA)
-Streptokinase
-Urokinase
Anticoagulants
-Heparins
-Unfractionated Heparin
-Low Molecular Weight Heparin (LMWH)
-Ultra-low Molecular Weight Heparin
-Vitamin K Antagonists
-Direct Thrombin Inhibitors
-Direct Factor Xa Inhibitors
By Application
Thrombocytosis
Pulmonary Embolism
Renal Impairment
Angina Blood Vessel Complications
Others
9 Europe Blood Preparation Market Analysis And Outlook To 2030
9.1 Introduction to Europe Blood Preparation Markets in 2024
9.2 Europe Blood Preparation Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Blood Preparation Market Size Outlook By Segments, 2021-2030
By Product
Whole Blood
-Red Cells
-Granulocytes
-Plasma
-Platelets
Blood Components
-Whole Blood Components
-Packed Red Cells
-Leukocyte Reduced Red Blood Cells
-Frozen Plasma
-Platelet Concentrate
-Cryoprecipitate
Blood Derivatives
By Antithrombotic and Anticoagulants Type
Platelet Aggregation Inhibitors
-Glycoprotein Inhibitors
-COX Inhibitors
-ADP Antagonists
-Others
Fibrinolytics
-Tissue Plasminogen Activator (tPA)
-Streptokinase
-Urokinase
Anticoagulants
-Heparins
-Unfractionated Heparin
-Low Molecular Weight Heparin (LMWH)
-Ultra-low Molecular Weight Heparin
-Vitamin K Antagonists
-Direct Thrombin Inhibitors
-Direct Factor Xa Inhibitors
By Application
Thrombocytosis
Pulmonary Embolism
Renal Impairment
Angina Blood Vessel Complications
Others
10 Asia Pacific Blood Preparation Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Blood Preparation Markets in 2024
10.2 Asia Pacific Blood Preparation Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Blood Preparation Market size Outlook by Segments, 2021-2030
By Product
Whole Blood
-Red Cells
-Granulocytes
-Plasma
-Platelets
Blood Components
-Whole Blood Components
-Packed Red Cells
-Leukocyte Reduced Red Blood Cells
-Frozen Plasma
-Platelet Concentrate
-Cryoprecipitate
Blood Derivatives
By Antithrombotic and Anticoagulants Type
Platelet Aggregation Inhibitors
-Glycoprotein Inhibitors
-COX Inhibitors
-ADP Antagonists
-Others
Fibrinolytics
-Tissue Plasminogen Activator (tPA)
-Streptokinase
-Urokinase
Anticoagulants
-Heparins
-Unfractionated Heparin
-Low Molecular Weight Heparin (LMWH)
-Ultra-low Molecular Weight Heparin
-Vitamin K Antagonists
-Direct Thrombin Inhibitors
-Direct Factor Xa Inhibitors
By Application
Thrombocytosis
Pulmonary Embolism
Renal Impairment
Angina Blood Vessel Complications
Others
11 South America Blood Preparation Market Analysis And Outlook To 2030
11.1 Introduction to South America Blood Preparation Markets in 2024
11.2 South America Blood Preparation Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Blood Preparation Market size Outlook by Segments, 2021-2030
By Product
Whole Blood
-Red Cells
-Granulocytes
-Plasma
-Platelets
Blood Components
-Whole Blood Components
-Packed Red Cells
-Leukocyte Reduced Red Blood Cells
-Frozen Plasma
-Platelet Concentrate
-Cryoprecipitate
Blood Derivatives
By Antithrombotic and Anticoagulants Type
Platelet Aggregation Inhibitors
-Glycoprotein Inhibitors
-COX Inhibitors
-ADP Antagonists
-Others
Fibrinolytics
-Tissue Plasminogen Activator (tPA)
-Streptokinase
-Urokinase
Anticoagulants
-Heparins
-Unfractionated Heparin
-Low Molecular Weight Heparin (LMWH)
-Ultra-low Molecular Weight Heparin
-Vitamin K Antagonists
-Direct Thrombin Inhibitors
-Direct Factor Xa Inhibitors
By Application
Thrombocytosis
Pulmonary Embolism
Renal Impairment
Angina Blood Vessel Complications
Others
12 Middle East And Africa Blood Preparation Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Blood Preparation Markets in 2024
12.2 Middle East and Africa Blood Preparation Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Blood Preparation Market size Outlook by Segments, 2021-2030
By Product
Whole Blood
-Red Cells
-Granulocytes
-Plasma
-Platelets
Blood Components
-Whole Blood Components
-Packed Red Cells
-Leukocyte Reduced Red Blood Cells
-Frozen Plasma
-Platelet Concentrate
-Cryoprecipitate
Blood Derivatives
By Antithrombotic and Anticoagulants Type
Platelet Aggregation Inhibitors
-Glycoprotein Inhibitors
-COX Inhibitors
-ADP Antagonists
-Others
Fibrinolytics
-Tissue Plasminogen Activator (tPA)
-Streptokinase
-Urokinase
Anticoagulants
-Heparins
-Unfractionated Heparin
-Low Molecular Weight Heparin (LMWH)
-Ultra-low Molecular Weight Heparin
-Vitamin K Antagonists
-Direct Thrombin Inhibitors
-Direct Factor Xa Inhibitors
By Application
Thrombocytosis
Pulmonary Embolism
Renal Impairment
Angina Blood Vessel Complications
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AstraZeneca plc
Baxter International Inc
Bristol-Myers Squibb Company
Celgene Corp
GlaxoSmithKline PLC
Leo Pharma A/S
Pfizer Inc
Portola Pharmaceuticals Inc
Sanofi
Shandong East Chemical Industry Co.
Xiamen Hisunny Chemical Co. Ltd
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Product
Whole Blood
-Red Cells
-Granulocytes
-Plasma
-Platelets
Blood Components
-Whole Blood Components
-Packed Red Cells
-Leukocyte Reduced Red Blood Cells
-Frozen Plasma
-Platelet Concentrate
-Cryoprecipitate
Blood Derivatives
By Antithrombotic and Anticoagulants Type
Platelet Aggregation Inhibitors
-Glycoprotein Inhibitors
-COX Inhibitors
-ADP Antagonists
-Others
Fibrinolytics
-Tissue Plasminogen Activator (tPA)
-Streptokinase
-Urokinase
Anticoagulants
-Heparins
-Unfractionated Heparin
-Low Molecular Weight Heparin (LMWH)
-Ultra-low Molecular Weight Heparin
-Vitamin K Antagonists
-Direct Thrombin Inhibitors
-Direct Factor Xa Inhibitors
By Application
Thrombocytosis
Pulmonary Embolism
Renal Impairment
Angina Blood Vessel Complications
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
The global Blood Preparation Market is one of the lucrative growth markets, poised to register a 6.5% growth (CAGR) between 2024 and 2032.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
AstraZeneca plc, Baxter International Inc, Bristol-Myers Squibb Company, Celgene Corp, GlaxoSmithKline PLC, Leo Pharma A/S, Pfizer Inc, Portola Pharmaceuticals Inc, Sanofi, Shandong East Chemical Industry Co., Xiamen Hisunny Chemical Co. Ltd
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume